# Phase 1 Clinical Trial MPC-2130 Treatment of Blood Cancers / Refractory Cancer

> **NCT00387153** · PHASE1 · TERMINATED · sponsor: **Myriad Therapeutics, Inc.** · enrollment: 8 (actual)

## Conditions studied

- Cancer

## Interventions

- **DRUG:** MPC-2130

## Key facts

- **NCT ID:** NCT00387153
- **Lead sponsor:** Myriad Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2005-08
- **Primary completion:** 2006-10
- **Final completion:** 2006-10
- **Target enrollment:** 8 (ACTUAL)
- **Why stopped:** Last subject enrolled experienced bradycardia; study was terminated by Sponsor.
- **Last updated:** 2009-11-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00387153

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00387153, "Phase 1 Clinical Trial MPC-2130 Treatment of Blood Cancers / Refractory Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00387153. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*